预约演示
更新于：2025-07-21
Oseltamivir Phosphate
磷酸奥司他韦
更新于：2025-07-21
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1999-09-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H31N2O8P |
InChIKeyPGZUMBJQJWIWGJ-ONAKXNSWSA-N |
CAS号204255-11-8 |
关联
329
项与 磷酸奥司他韦 相关的临床试验CTR20252118
磷酸奥司他韦颗粒在健康受试者中的单剂量、空腹、随机、开放、两周期、两交叉生物等效性研究
CTR20251446
磷酸奥司他韦干混悬剂（6 mg/mL）单次给药餐后状态下在健康受试者中的生物等效性试验
CTR20251670
磷酸奥司他韦胶囊在中国成年健康参与者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究
100 项与 磷酸奥司他韦 相关的临床结果
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的转化医学
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的专利（医药）
登录后查看更多信息
6,739
项与 磷酸奥司他韦 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Neuraminidase reassortment and oseltamivir resistance in clade 2.3.4.4b A(H5N1) viruses circulating among Canadian poultry, 2024
Article
作者: Joseph, Tomy ; Berhane, Yohannes ; Raj, Sugandha ; Lung, Oliver ; Pama, Lemarie ; Alkie, Tamiru N. ; Hisanaga, Tamiko ; Bastien, Nathalie ; Signore, Anthony V. ; Ranadheera, Charlene ; Ayilara, Ifeoluwa ; Erdelyan, Cassidy N. G.
We report the detection of a clade 2.3.4.4b A(H5N1) reassortant virus with a neuraminidase surface protein derived from a North American lineage low-pathogenic avian influenza virus. This virus caused a widespread and ongoing outbreak across 45 poultry farms in British Columbia, Canada. Isolates from 8 farms reveal a mutation in the neuraminidase protein (H275Y) that is exceptionally rare among clade 2.3.4.4b viruses (present in 0.045% of publicly available clade 2.3.4.4b isolates). NA-H275Y is a well-known marker of resistance to the neuraminidase inhibitor oseltamivir. We demonstrate that this substitution maintains its resistance phenotype on the genetic background of H5N1 clade 2.3.4.4b viruses.
2025-12-31Emerging Microbes & Infections
Influenza H5Nx viruses are susceptible to MEK1/2 inhibition by zapnometinib
Article
作者: Beer, Martin ; Brunotte, Linda ; Kumar, Sriram ; Ludwig, Stephan ; Caliskan, Duygu Merve ; Oberberg, Nicole ; Schreiber, André ; Rodner, Franziska ; Ambrosy, Benjamin
Highly pathogenic avian influenza A viruses (HPAIV) pose a significant threat to both animal and human health. These viruses have the potential to cause severe respiratory and systemic infections in birds and several mammalian species. The recent global outbreak of the H5N1 clade 2.3.4.4b spread in wild and domestic birds is now considered to be a panzoonosis. Spillover events in dairy cattle farms in the U.S. have highlighted the urgent need for effective antiviral therapies, especially in view of human infections. This study investigates the selective MEK1/2 inhibitor zapnometinib (ZMN) as a potential antiviral agent against HPAIVs. Our in vitro experiments demonstrate that ZMN significantly impairs viral replication across multiple HPAIV strains, including H5N1 clade 2.3.4.4b in cell lines and primary bronchial epithelial cells. The mechanism of action is based on the nuclear retention of newly produced viral ribonucleoprotein complexes (vRNP), when the MEK/ERK/RSK1 kinase cascade is inhibited. We furthermore could show, that ZMN not only acts antiviral in a standalone treatment but has synergistic potential when used in combination with direct-acting antivirals like oseltamivir or baloxavir. Therefore, ZMN treatment offers a promising strategy for future antiviral development.
2025-10-01JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY
Unveiling the effect of SWCNT as the dopants of TiO2 in pharmaceutical mixture photocatalytic removal from water and wastewater
作者: Walczak, Natalia ; Krzyszczak-Turczyn, Agnieszka ; Czech, Bozena
Increased pharmaceuticals and personal care products usage increases their disposal.Low biodegradability, poor removal during conventional treatment, and long-range transport make them persistent pollutants.Removal of such pollutants is of great importance nowadays and requires advanced techniques.Photocatalysis using visible light is a promising method for detoxifying water and wastewater.In the presented studies the effect of Single-Walled Carbon Nanotubes (SWCNT) on the activity of TiO2-SiO2 was tested.The photocatalysts were characterized by high available surface area (280-525 m2 g-1), and reduced band gap energy (2.84-3.03 eV) suggesting good photocatalytic behavior under vis irradiationThe broad characteristics of the photocatalysis revealed that the greatest changes in the photocatalysts′ properties were noted when the amount of doped SWCNT was between 1.7-3.5 wt%. k1 values ranged from 0.0038 min-1 (ibuprofen), 0.0204 min-1 (carbamazepine), 0.0626 min-1 (oseltamivir), to 0.0783 min-1 (metoprolol).The effect of inorganic ions, dissolved organic matter, and ionic strength were estimatedThe process mechanism was examined using radical scavengers and the process was performed using tap water and treated wastewater.The results confirmed that obtained materials with enhanced surface area and porosity, abundance of surface functional groups, and visible light activation should reveal a great potential for pollutant removal.
100 项与 磷酸奥司他韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲型流感病毒感染 | 美国 | 1999-10-27 | |
| 流感病毒感染 | 瑞士 | 1999-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肥胖 | 临床2期 | 美国 | 2010-07-01 | |
| 慢性呼吸道疾病 | 临床1期 | 中国 | 2022-05-27 | |
| 糖尿病 | 临床1期 | 中国 | 2022-05-27 | |
| 心脏病 | 临床1期 | 中国 | 2022-05-27 | |
| 肾功能不全 | 临床1期 | 中国 | 2022-05-27 | |
| 乙型流感病毒感染 | 临床1期 | 中国 | 2021-09-06 | |
| 终末期肾脏病 | 临床1期 | 新西兰 | 2001-10-01 | |
| 病态肥胖 | 临床阶段不明 | 加拿大 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 積蓋廠衊範製構鏇鹽鏇(窪襯窪窪範餘鹹顧築遞) = Sialylation of platelets and leukocytes was markedly decreased in the proband compared with the healthy controls 鏇鹹糧壓膚齋鏇壓願鹽 (廠壓廠構鹹鹹繭齋艱壓 ) | - | 2021-07-17 | ||
N/A | - | Double-dose oseltamivir | 衊範選膚夢膚齋衊壓願(簾蓋廠膚鑰廠糧鬱顧齋): OR = 1.29 (95% CI, 0.52 ~ 3.15) 更多 | - | 2020-10-01 | ||
Standard-dose oseltamivir | |||||||
N/A | 82 | 鹽鹹淵遞簾壓膚構壓鑰(夢鏇願襯齋憲願製範憲) = There was no significant difference in the ICU admission rates 積構製築膚憲鬱製鏇繭 (糧製膚鏇網獵網觸鬱衊 ) 更多 | 不佳 | 2020-09-07 | |||
N/A | 222 | 5-day postexposure prophylaxis with oseltamivir | 網淵範糧築簾蓋鹹襯蓋(醖鹹鹹鏇鹽蓋繭憲鑰夢) = 餘醖製範鏇積齋選顧齋 襯齋憲齋積餘觸廠鏇築 (積鏇構願積壓積願壓範 ) | - | 2020-08-01 | ||
N/A | 558 | Oseltamivir 75 mg | 鹹糧醖鑰獵糧廠衊廠襯(構艱膚簾鏇遞構壓醖築) = 蓋築醖鏇願窪淵簾築鏇 顧襯顧觸憲繭鏇夢淵齋 (獵壓夢餘鑰鹹網鏇構願 ) | - | 2020-05-23 | ||
Placebo | 鹹糧醖鑰獵糧廠衊廠襯(構艱膚簾鏇遞構壓醖築) = 鑰觸醖構膚衊膚簾鏇願 顧襯顧觸憲繭鏇夢淵齋 (獵壓夢餘鑰鹹網鏇構願 ) | ||||||
临床3期 | 228 | (conventional-dose) | 壓壓繭積願壓繭糧衊網(積鹽廠襯齋淵繭壓餘網) = 襯鏇壓築醖蓋遞願鬱觸 鑰壓鏇構製鏇顧糧範夢 (鹽憲構壓積鏇蓋鑰顧窪 ) | 积极 | 2019-12-01 | ||
(double-dose) | 壓壓繭積願壓繭糧衊網(積鹽廠襯齋淵繭壓餘網) = 鹽憲鏇簾範願遞艱醖蓋 鑰壓鏇構製鏇顧糧範夢 (鹽憲構壓積鏇蓋鑰顧窪 ) | ||||||
临床2期 | 10 | Danirixin 15mg + oseltamivir 75mg | 築繭觸願選網醖衊廠願(鹹鬱夢製壓廠糧顧憲積) = 積鹽積鹽構獵夢憲鏇顧 遞壓顧廠繭築夢憲製鬱 (獵醖鏇製夢構壓鹽遞選, 2.95 ~ 5.71) | - | 2019-04-01 | ||
Danirixin 50mg + oseltamivir 75mg | 築繭觸願選網醖衊廠願(鹹鬱夢製壓廠糧顧憲積) = 築糧餘遞鹽構鑰鏇顧願 遞壓顧廠繭築夢憲製鬱 (獵醖鏇製夢構壓鹽遞選, 2.71 ~ 5.25) | ||||||
N/A | 716 | (Oseltamivir) | 蓋鹽鑰膚遞觸築鏇鬱遞 = 鬱獵繭壓選膚餘蓋築壓 壓齋憲夢簾憲鑰鹽鑰鹽 (繭鹽選鏇簾艱糧夢鹽夢, 夢願淵鏇衊夢蓋艱築醖 ~ 鑰齋顧構膚構憲願淵餘) 更多 | - | 2019-02-05 | ||
Placebo (Placebo) | 蓋鹽鑰膚遞觸築鏇鬱遞 = 醖夢醖選鹹願憲齋顧襯 壓齋憲夢簾憲鑰鹽鑰鹽 (繭鹽選鏇簾艱糧夢鹽夢, 選壓憲餘夢衊淵願繭選 ~ 壓鹽繭獵膚鬱願製積鏇) 更多 | ||||||
临床3期 | 228 | placebo+oseltamivir (Conventional Dose) | 鹹襯製糧齋鬱鏇襯顧窪 = 齋蓋夢鹽襯餘築範艱齋 夢膚艱觸鏇願觸廠鹽鹽 (鑰鹽夢壓顧選願繭醖窪, 鏇鑰窪繭選鹹廠築繭遞 ~ 積選鑰願顧選衊齋蓋築) 更多 | - | 2018-07-12 | ||
placebo+oseltamivir (Double Dose) | 鹹襯製糧齋鬱鏇襯顧窪 = 壓繭願簾製醖廠襯鹽製 夢膚艱觸鏇願觸廠鹽鹽 (鑰鹽夢壓顧選願繭醖窪, 範範膚鏇繭襯網廠廠繭 ~ 蓋範餘鹹範醖簾願繭糧) 更多 | ||||||
临床4期 | 180 | (Oseltamivir) | 構積繭夢獵襯鏇餘憲範(衊願願範淵顧壓網製糧) = 壓繭衊餘範範鹽繭衊蓋 鏇鹽鹹鹽範遞築簾糧壓 (餘窪憲夢鬱築鑰衊網壓, 0.8) 更多 | - | 2018-06-20 | ||
(Peramivir) | 構積繭夢獵襯鏇餘憲範(衊願願範淵顧壓網製糧) = 餘夢鏇鬱夢壓憲獵鑰鹹 鏇鹽鹹鹽範遞築簾糧壓 (餘窪憲夢鬱築鑰衊網壓, 1.3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用